BioWorld

April 28, 2008

Astellas, CoMentis in $760M Deal for Alzheimer's Treatment

Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today) Read More

FDA OKs Progenics Drug; EMA also Gives It a Nod

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

Observational Trials Have Merits, but Stark Limits also Apparent

Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab

Isis Shares Slip on Need for Mipomersen Data

House Measure Reauthorizes BIO-Backed SBIR Grants

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...